Journal of Molecular Medicine

, Volume 81, Issue 12, pp 766–779 | Cite as

Paraoxonase gene polymorphisms, oxidative stress, and diseases

  • Hong-Liang Li
  • De-Pei LiuEmail author
  • Chih-Chuan Liang


The paraoxonase (PON) gene cluster contains at least three members, including PON1, PON2, and PON3, located on chromosome 7q21.3–22.1. Until now there has been little insight into the role of the respective gene products in human physiology and pathology. However, emerging evidence from biochemical and genetic experiments is providing clues about the role(s) of the products of these genes, which indicates that PON(s) acts as important guardians against cellular damage from toxic agents, such as organophosphates, oxidized lipids in the plasma low-density lipoproteins. In parallel, substantial data have been published on the association between the polymorphisms of PON(s) and coronary heart disease. It has become clear that the polymorphisms significantly affect the prevalence of coronary heart disease. However, the associations between the PON(s) polymorphisms and most of these conditions were found to be inconsistent when additional populations were investigated. This contribution provides an overview of the status of research of each of the three genes and the available association studies and the potential problems in interpreting the data. We also review the current evidence on the association between PON(s) polymorphisms and diseases other than coronary heart disease and some metabolic quantitative phenotypes, such as plasma lipoproteins, plasma glucose, and birthweight. Finally, we suggest directions for the future that might elucidate the role of the PON genetic polymorphisms in this potentially important function of PON(s) and the role in coronary heart disease and other related diseases.


Paraoxonase Coronary heart disease Polymorphism Atherosclerosis Review 



Alzheimer’s dementia




Coronary heart disease


High-density lipoprotein


Low-density lipoprotein


Parkinson’s disease





This work is supported by “973” Basic Research Funding Scheme of China (G2000056902).


  1. 1.
    Costa LG, Cole TB, Jarvik GP and Furlong CE (2003) Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease and drug metabolism. Annu Rev Med 54:371–392CrossRefPubMedGoogle Scholar
  2. 2.
    Costa LG, Furlong CE (2003) Paraoxonase (PON1) in health and disease: basic and clinical aspects. Kluwer Norwell, pp 165–183Google Scholar
  3. 3.
    Mackness B, Durrington PN, Mackness MI (2002) The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 13:357–362CrossRefPubMedGoogle Scholar
  4. 4.
    Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, Kano K (2001) Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraxonase 1 gene (Q192R) polymorphism? Eur J Endocrinol 144:639–644PubMedGoogle Scholar
  5. 5.
    Ito T, Yasue H, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, Mizuno Y, Kawano H, Ogawa H (2002) Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Hum Genet 110:89–94CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M (2002) Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106:740–745PubMedGoogle Scholar
  7. 7.
    Cherry N, Mackness M, Durrington P, Povey A, Dippnall M, Smith T, Mackness B (2002) Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 359:763–764CrossRefPubMedGoogle Scholar
  8. 8.
    Worth J (2002) Paraoxonase polymorphisms and organophosphates. Lancet 360:802–803CrossRefPubMedGoogle Scholar
  9. 9.
    Allebrandt KV, Souza RL, Chautard-Freire-Maia EA (2002) Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians. Toxicol Appl Pharmacol 180:151–156Google Scholar
  10. 10.
    Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J (2002) Paraoxonase 192 Gln→Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 33:1459–1464CrossRefPubMedGoogle Scholar
  11. 11.
    Yamada M, Sodeyama N, Itoh Y, Otomo E, Matsushita M, Mizusawa H (2002) No association of paraoxonase genotype or atherosclerosis with cerebral amyloid angiopathy. Stroke 33:896–900CrossRefPubMedGoogle Scholar
  12. 12.
    Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa PP, Ricci G, Verna R, Pannitteri G (2002) PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 32:9–15CrossRefGoogle Scholar
  13. 13.
    Sangvanich P, Mackness B, Gaskell SJ, Durrington P, Mackness M (2003) The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. Biochem Biophys Res Commun 300:501–506CrossRefPubMedGoogle Scholar
  14. 14.
    Malin R, Knuuti J, Janatuinen T, Laaksonen R, Vesalainen R, Nuutila P, Jokela H, Laakso J, Jaakkola O, Solakivi T, Lehtimaki T (2001) Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 79:449–458CrossRefPubMedGoogle Scholar
  15. 15.
    Rowles J, Scherer SW, Xi T, Majer M, Nickle DC, Rommans JM, Popov KM, Harris RA, Riebow NL, Xia J (1996) Cloning and characterisation of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human. J Biol Chem 271:22376–22382CrossRefPubMedGoogle Scholar
  16. 16.
    Mackness B, Durrington PN, Abuashia B, Boulton AJM, Mackness MI (2000) Low paraoxonase activity in type II diabetes complicated by retinopathy. Clin Sci (Colch) 98:355–363Google Scholar
  17. 17.
    Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435–33442CrossRefPubMedGoogle Scholar
  18. 18.
    Josse D, Ebel C, Stroebel D, Fontaine A, Borges F, Echalier A, Baud D, Renault F, Le Maire M, Chabrieres E, Masson P (2002) Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1). J Biol Chem 277:33386–33397CrossRefPubMedGoogle Scholar
  19. 19.
    Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473–480PubMedGoogle Scholar
  20. 20.
    La Du BN (1996) Structural and functional diversity of paraoxonases. Nat Med 2:1186–1187PubMedGoogle Scholar
  21. 21.
    Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW (2002) Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277:4301–4308CrossRefPubMedGoogle Scholar
  22. 22.
    Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM (2001) HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21:481–488PubMedGoogle Scholar
  23. 23.
    Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ (2000) Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275:17527–17535CrossRefPubMedGoogle Scholar
  24. 24.
    Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284–287Google Scholar
  25. 25.
    Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM (2002) Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106:484–490CrossRefPubMedGoogle Scholar
  26. 26.
    Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM (2002) Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 290:921–927CrossRefPubMedGoogle Scholar
  27. 27.
    Van Lenten BJ, Wagner AC, Navab M, Fogelman AM (2001) Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 276:1923–1929CrossRefPubMedGoogle Scholar
  28. 28.
    Ahmed Z, Babaei S, Maguire GF, Draganov D, Kuksis A, La Du BN, Connelly PW (2003) Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. Cardiovasc Res 57:225–231CrossRefPubMedGoogle Scholar
  29. 29.
    Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2001) Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J Biol Chem 276:24473–24481CrossRefPubMedGoogle Scholar
  30. 30.
    Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101:1581–1590PubMedGoogle Scholar
  31. 31.
    Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2002) Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem Biophys Res Commun 290:391–396CrossRefPubMedGoogle Scholar
  32. 32.
    Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101:2510–2517PubMedGoogle Scholar
  33. 33.
    Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE (2002) Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 22:1329–1333CrossRefPubMedGoogle Scholar
  34. 34.
    Arrol S, Mackness MI, Durrington PN (1996) Low density lipoprotein associated with enzymes and the prevention of low-density lipoprotein oxidation. Eur J Lab Med 4:33–48Google Scholar
  35. 35.
    Rodrigo L, Hernandez AF, Lopez-Caballero JJ, Gil F, Pla A (2001) Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 137:123–137CrossRefPubMedGoogle Scholar
  36. 36.
    Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE (2003) Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13:357–364CrossRefPubMedGoogle Scholar
  37. 37.
    Feingold KR, Memon RA, Moser AH (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139:307–315CrossRefPubMedGoogle Scholar
  38. 38.
    Aviram M, Rosenblat M, Billecke S (1999) Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:892–904PubMedGoogle Scholar
  39. 39.
    Ferre N, Camps J, Cabre M (2001) Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 50:997–1000PubMedGoogle Scholar
  40. 40.
    Gonzalvo MC, Gil F, Hernandez AF et al (1997) Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials Chem Biol Interact 105:169–179Google Scholar
  41. 41.
    James RW, Leviev I, Righetti A (2000) Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252–2257PubMedGoogle Scholar
  42. 42.
    Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73–76PubMedGoogle Scholar
  43. 43.
    Adkins S, Gan KN, Mody M, La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52:598–608Google Scholar
  44. 44.
    Watson CE, Draganov DI, Billecke SS, Bisgaier CL, La Du BN (2001) Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Pharmacogenetics 11:123–134CrossRefPubMedGoogle Scholar
  45. 45.
    Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435–442PubMedGoogle Scholar
  46. 46.
    Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141:259–264CrossRefPubMedGoogle Scholar
  47. 47.
    Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardaji A, Camps J, Richart C, Joven J (2002) Paraoxonase Gln-Arg (192) and Leu-Met (55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 35:197–203CrossRefPubMedGoogle Scholar
  48. 48.
    Furlong CE, Cole TB, Jarvik GP, Costa LG (2002) Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 3:341–348Google Scholar
  49. 49.
    Leviev I, Poirier O, Nicaud V, Evans A, Kee F, Arveiler D, Morrisson C, Cambien F, James RW (2002) High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis 161:463–467CrossRefPubMedGoogle Scholar
  50. 50.
    Leviev I, Kalix B, Brulhart Meynet MC, James RW (2001) The paraoxonase PON1 promoter polymorphism C (-107) T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia 44:1177–1183CrossRefPubMedGoogle Scholar
  51. 51.
    Leviev I, Righetti A, James RW (2001) Paraoxonase promoter polymorphism T (-107) C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 79:457–463CrossRefPubMedGoogle Scholar
  52. 52.
    Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE (2001) Effects of 5’ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428–1436CrossRefPubMedGoogle Scholar
  53. 53.
    Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE (2001) Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77–84CrossRefPubMedGoogle Scholar
  54. 54.
    Leviev I, James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516–521PubMedGoogle Scholar
  55. 55.
    James RW, Leviev I, Righetti A (2000) Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252–2257PubMedGoogle Scholar
  56. 56.
    Hedrick CC, Hassan K, Hough GP, Yoo JH, Simzar S, Quinto CR, Kim SM, Dooley A, Langi S, Hama SY, Navab M, Witztum JL, Fogelman AM (2000) Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol 20:1946–1952PubMedGoogle Scholar
  57. 57.
    Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM (2001) High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 103:2283–2288PubMedGoogle Scholar
  58. 58.
    Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM (2002) Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106:1127–1132CrossRefPubMedGoogle Scholar
  59. 59.
    De Roos NM, Schouten EG, Scheek LM, van Tol A, Katan MB (2002) Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women. Metabolism 51:1534–1537CrossRefPubMedGoogle Scholar
  60. 60.
    Freese R, Alfthan G, Jauhiainen M, Basu S, Erlund I, Salminen I, Aro A, Mutanen M (2002) High intakes of vegetables, berries, and apples combined with a high intake of linoleic or oleic acid only slightly affect markers of lipid peroxidation and lipoprotein metabolism in healthy subjects. Am J Clin Nutr 76:950–960PubMedGoogle Scholar
  61. 61.
    Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G, Aro A, Kesaniemi YA (2002) Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 132:3012–3017PubMedGoogle Scholar
  62. 62.
    Hegele RA (1999) Paraoxonase genes and disease. Ann Med 31:217–224PubMedGoogle Scholar
  63. 63.
    Leus FR, Zwart M, Kastelein JJ, Voorbij HA (2001) PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 154:641–649CrossRefPubMedGoogle Scholar
  64. 64.
    Ikeda T, Obayashi H, Hasegawa G, Nakamura N, Yoshikawa T, Imamura Y, Koizumi K, Kinoshita S (2001) Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. Am J Ophthalmol 132:191–195CrossRefPubMedGoogle Scholar
  65. 65.
    Fanella S, Harris SB, Young TK, Hanley AJ, Zinman B, Connelly PW, Hegele RA (2000) Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin Chem Lab Med 38:413–420PubMedGoogle Scholar
  66. 66.
    Malin R, Laaksonen R, Knuuti J, Janatuinen T, Vesalainen R, Nuutila P, Lehtimaki T (2001) Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 11:625–633CrossRefPubMedGoogle Scholar
  67. 67.
    Watzinger N, Schmidt H, Schumacher M, Schmidt R, Eber B, Fruhwald FM, Zweiker R, Kostner GM, Klein W (2002) Human paraoxonase1 gene polymorphisms and the risk of coronary heart disease: a community-based study. Cardiology 98:116–122CrossRefPubMedGoogle Scholar
  68. 68.
    Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451–1457PubMedGoogle Scholar
  69. 69.
    Bonafe M, Marchegiani F, Cardelli M, Olivieri F, Cavallone L, Giovagnetti S, Pieri C, Marra M, Antonicelli R, Troiano L, Gueresi P, Passeri G, Berardelli M, Paolisso G, Barbieri M, Tesei S, Lisa R, De Benedictis G, Franceschi C (2002) Genetic analysis of paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur J Hum Genet 10:292–296CrossRefPubMedGoogle Scholar
  70. 70.
    Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99:62–66PubMedGoogle Scholar
  71. 71.
    Murphy MM, Vilella E, Ceruelo S, Figuera L, Sanchez M, Camps J, Cuco G, Ferre N, Labad A, Tasevska N, Arija V, Joven J, Fernandez-Ballart J (2002) The MTHFR C677T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors. Clin Chem 48:372–375PubMedGoogle Scholar
  72. 72.
    Jarvik GP, Rozek LS, Brophy VH (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 20:2441–2447PubMedGoogle Scholar
  73. 73.
    James RW, Leviev I, Ruiz J (2000) Promoter polymorphism T (-107) C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49:1390–1393PubMedGoogle Scholar
  74. 74.
    Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444–44449CrossRefPubMedGoogle Scholar
  75. 75.
    Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, Tsui LC, Prochazka M (1998) Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213:149–157CrossRefPubMedGoogle Scholar
  76. 76.
    Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui LC, Hegele RA (1998) Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 139:131–136CrossRefPubMedGoogle Scholar
  77. 77.
    Gunnarsdottir I, Birgisdottir BE, Thorsdottir I, Gudnason V, Benediktsson R (2002) Size at birth and coronary artery disease in a population with high birth weight. Am J Clin Nutr 76:1290–1294PubMedGoogle Scholar
  78. 78.
    Bhopal R, Fischbacher CM (2002) Many South Asian people probably need pre-diabetes care. BMJ 325:965CrossRefGoogle Scholar
  79. 79.
    Cassell PG, Jackson AE, North BV, Evans JC, Syndercombe-Court D, Phillips C, Ramachandran A, Snehalatha C, Gelding SV, Vijayaravaghan S, Curtis D, Hitman GA (2002) Haplotype combinations of calpain 10 gene polymorphisms associate with increased risk of impaired glucose tolerance and type 2 diabetes in South Indians. Diabetes 51:1622–1628PubMedGoogle Scholar
  80. 80.
    Busch CP, Ramdath DD, Ramsewak S, Hegele RA (1999) Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. Pharmacogenetics 9:351–356PubMedGoogle Scholar
  81. 81.
    Chen Q, Reis SE, Kammerer CM, McNamara DM, Holubkov R, Sharaf BL, Sopko G, Pauly DF, Merz CN, Kamboh MI (2003) Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 72:13–22CrossRefPubMedGoogle Scholar
  82. 82.
    Pan JP, Lai ST, Chiang SC, Chou SC, Chiang AN (2002) The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei) 65:415–421Google Scholar
  83. 83.
    Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J (2001) Paraoxonase2 polymorphisms are associated with nephropathy in type II diabetes. Diabetologia 44:104–107PubMedGoogle Scholar
  84. 84.
    Kao YL, Donaghue K, Chan A, Knight J, Silink A (1998) A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab 83:2589–2592PubMedGoogle Scholar
  85. 85.
    Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, Silink M, Donaghue K (2001) Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 50:657–660CrossRefPubMedGoogle Scholar
  86. 86.
    Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Ito H, Kumon Y, Hashimoto K (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598–602PubMedGoogle Scholar
  87. 87.
    Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI (2000) Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Colch) 98:355–363Google Scholar
  88. 88.
    Araki S, Makita Y, Canani L, Ng D, Warram JH, Krolewski AS (2000) Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in type I diabetes mellitus. Diabetologia 43:1540–1543PubMedGoogle Scholar
  89. 89.
    Canani LH, Araki S, Warram JH, Krolewski AS (2001) Comment-to: Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J (2001) Paraoxonase 2 polymorphisms are associated with diabetic nephropathy in type II diabetes. Diabetologia 44:104–107. Diabetologia 44:1062–1064PubMedGoogle Scholar
  90. 90.
    Kao Y, Donaghue KC, Chan A, Bennetts BH, Knight J, Silink M (2002) Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. Diabet Med 19:212–215CrossRefPubMedGoogle Scholar
  91. 91.
    Carmine A, Buervenich S, Sydow O, Anvret M, Olson L (2002) Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson’s disease. Mov Disord 17:764–766CrossRefPubMedGoogle Scholar
  92. 92.
    Akhmedova SN, Yakimovsky AK, Schwartz EI (2001) Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson’s disease. J Neurol Sci 184:179–182CrossRefPubMedGoogle Scholar
  93. 93.
    Konda I, Yamamoto M (1998) Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson’s disease. Brain Res 806:271–273CrossRefPubMedGoogle Scholar
  94. 94.
    Wang J, Liu Z (2000) No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson’s disease in a Chinese population. Mov Disord 15:1265–1267CrossRefPubMedGoogle Scholar
  95. 95.
    Dantoine TF, Drouet M, Debord J, Merle L, Cogne M, Charmes JP (2002) Paraoxonase 1 192/55 gene polymorphisms in Alzheimer’s disease. Ann N Y Acad Sci 977:239–244PubMedGoogle Scholar
  96. 96.
    Janka Z, Juhasz A, Rimanoczy AA, Boda K, Marki-Zay J, Kalman J (2002) Codon 311 (Cys→–Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer’s and vascular dementias. Mol Psychiatry 7:110–112CrossRefPubMedGoogle Scholar
  97. 97.
    Zuliani G, Ble’ A, Zanca R, Munari MR, Zurlo A, Vavalle C, Atti AR, Fellin R (2001) Genetic polymorphisms in older subjects with vascular or Alzheimer’s dementia. Acta Neurol Scand 103:304–308CrossRefPubMedGoogle Scholar
  98. 98.
    Nassar BA, Darvesh S, Bevin LD, Rockwood K, Kirkland SA, O’Neill BJ, Bata IR, Johnstone DE, Title LM (2002) Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease. Clin Biochem 35:205–209CrossRefPubMedGoogle Scholar
  99. 99.
    Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O (2001) Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6:66–73CrossRefPubMedGoogle Scholar
  100. 100.
    Matsumoto C, Ohmori O, Hori H, Shinkai T, Nakamura J (2002) Analysis of association between the Gln192Arg polymorphism of the paraoxonase gene and schizophrenia in humans. Neurosci Lett 321:165–168CrossRefPubMedGoogle Scholar
  101. 101.
    Barbieri M, Bonafe M, Marfella R, Ragno E, Giugliano D, Franceschi C, Paolisso G (2002) LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. J Clin Endocrinol Metab 87:222–225Google Scholar
  102. 102.
    Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A (2002) Association between xenobiotic gene polymorphisms and non-Hodgkin’s lymphoma risk. Br J Haematol 118:477–448CrossRefPubMedGoogle Scholar
  103. 103.
    Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435–33442CrossRefPubMedGoogle Scholar
  104. 104.
    Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21:542–547PubMedGoogle Scholar
  105. 105.
    Heinecke JW, Lusis AJ (1998) Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 62:20–24CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.National Laboratory of Medical Molecular Biology, Institute of Basic Medical SciencesChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingP.R. China

Personalised recommendations